NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Forecast & News

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ZEALAND PHARMA/S.

5 brokerages have issued 12 month price targets for ZEALAND PHARMA/S's stock. Their forecasts range from $38.00 to $42.00. On average, they anticipate ZEALAND PHARMA/S's share price to reach $40.33 in the next year. This suggests a possible upside of 6.3% from the stock's current price. View Analyst Price Targets for ZEALAND PHARMA/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ZEALAND PHARMA/S.

Media coverage about ZEAL stock has trended somewhat positive on Tuesday, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a news impact score of 1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for ZEALAND PHARMA/S.

Some companies that are related to ZEALAND PHARMA/S include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), FibroGen (FGEN), Nektar Therapeutics (NKTR), Mirati Therapeutics (MRTX), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), Zai Lab (ZLAB), Emergent Biosolutions (EBS), SAGE Therapeutics (SAGE), Ultragenyx Pharmaceutical (RARE) and PTC Therapeutics (PTCT).

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), Tandem Diabetes Care (TNDM), Ford Motor (F), Wells Fargo & Co (WFC), NVIDIA (NVDA), Alibaba Group (BABA) and Tesla (TSLA).

(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

ZEALAND PHARMA/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.09%), Jane Street Group LLC (0.04%) and Rockefeller Capital Management L.P. (0.03%).

ZEAL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Rockefeller Capital Management L.P. and Jane Street Group LLC.

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZEAL stock can currently be purchased for approximately $37.93.

ZEALAND PHARMA/S has a market capitalization of $1.37 billion and generates $6.02 million in revenue each year. The company earns $92.07 million in net income (profit) each year or $3.00 on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.View Additional Information About ZEALAND PHARMA/S.

The official website for ZEALAND PHARMA/S is http://www.zealandpharma.com/.

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]